GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
GeNeuro (Paris:GNRO):
Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com
| Date |
|
Number of shares
outstanding
|
|
Total voting rights,
gross (1) |
|
Total voting rights,
net (2) |
| May 31, 2016 |
|
14 658 118 |
|
14 658 118 |
|
14 596 551 |
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold
crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares
to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking
into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the
liquidity contract). It is released in order to ensure that the public is properly informed, in accordance with the AMF
recommendation of July 17, 2017.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as
multiple sclerosis by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human
DNA; a new frontier pioneered by GeNeuro since 2006 based on 15 years of R&D at Institut Mérieux and INSERM.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 23 employees and
rights to 16 patent families protecting its technology.
For more information, visit: www.geneuro.com
GeNeuro
Jesús Martin-Garcia, +41 22 794 50 85
Chairman and CEO
investors@geneuro.com
or
NewCap (France)
Julien Perez, 01 44 71 98 52
(Investors)
or
Nicolas Merigeau, 01 44 71 94 98
(media)
geneuro@newcap.eu
View source version on businesswire.com: http://www.businesswire.com/news/home/20160603005262/en/